LISTING OF CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Previously presented) A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally substituted, fused benzene;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

2-3. (Cancelled)

4. (Previously presented) A method according to claim 1, wherein the fused benzene is unsubstituted.

5. to 9. (Cancelled).

10. (Currently amended) A method according to claim 1, wherein R_L is substituted by one or more substituents selected from the group consisting of: C_{1-7} alkyl; C_{5-20} aryl; C_{3-20} heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; ~~acylamido~~ acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

11. (Currently amended) A method according to claim 10, wherein R_L is substituted by ~~an acylamido, wherein the acylamido is~~ a ureido group, or ~~an amino, wherein the amino is~~ a sulfonamido group.

12. (Original) A method according to claim 1, wherein the disease mediated by PARP is cancer, and there is additionally administered to the subject chemotherapy or radiation therapy.

13. (Previously presented) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally substituted, fused benzene;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

14. (Currently amended) A compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally monosubstituted, fused benzene;

R_C is $-CH_2-R_L$;

R_L is substituted phenyl, wherein the substituents are selected from the group consisting of: ~~C_{5-20} aryl;~~ C_{3-20} heterocyclyl; ester; amido; acyloxy; sulfonamido; ~~cyano;~~ ureido; ~~acylamido; thioether; thiol; SO_2R wherein R is C_{1-7} alkyl, C_{3-20} heterocyclyl or C_{5-20} aryl; and sulfoxide;~~ and optionally further substituted; and

R_N is hydrogen.

15-16. (Cancelled)

17. (Previously presented) A compound according to claim 14, wherein the fused benzene is unsubstituted.

18. (Cancelled)

19. (Currently amended) A compound according to claim 14, wherein R_L is substituted by ~~an acylamido, wherein the acylamido is~~ a ureido group, or a sulfonamido group.

20. (Previously presented) A pharmaceutical composition comprising a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused benzene;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen;

and a pharmaceutically acceptable carrier or diluent.

21-22. (Cancelled)

23. (Previously presented) The pharmaceutical composition of claim 20, wherein the fused benzene is unsubstituted.

24. (Currently amended) The pharmaceutical composition of claim 20, wherein R_L is substituted by one or more substituents selected from the group consisting of: C_{1-7} alkyl; C_{5-20} aryl; C_{3-20} heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; ~~acylamido~~ acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

25. (Currently amended) The pharmaceutical composition of claim 24, wherein R_L is substituted by ~~an acylamido, wherein the acylamido is~~ a ureido group, or ~~an amino, wherein the amino is~~ a sulfonamido group.

26. (Currently amended) A method of treatment of a disease of a human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of the formula:





or an isomer, salt, solvate, chemically protected form and prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

27. (Currently amended) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof.

28. (Currently amended) A compound of the formula:





or an isomer, salt, solvate, chemically protected form and prodrug thereof.